Scaling a Dental Support Organization (DSO) used to be a game of rapid-fire checkers. In the "buy-everything" era, the strategy was simple: identify a practice with decent EBITDA, write the check, and bolt it onto the platform. If the culture was a little off or the systems were antiquated, we told ourselves we’d fix it in the post-close integration.

But as we settle into 2026, the board has changed.

The low-hanging fruit has been picked, and what’s left on the acquisition market is often overpriced, under-staffed, or carrying a heavy burden of "culture debt." For the modern COO, the math on acquisitions is no longer as clean as it was five years ago. We are seeing a fundamental shift in the industry, a move away from the frantic chase of M&A toward the intentional, sustainable strategy of De Novo growth.

At Arthur Marshall, we aren’t just watching this shift from the sidelines. We are in the trenches with you. We’re seeing that the smartest groups aren’t just looking to grow; they are looking to mature. They are trading the "quick win" of a messy acquisition for the long-term ROI of building a practice from the ground up.

The Hidden Cost of the "M&A Hangover"

Let’s be honest about the state of acquisitions today. When you buy a practice in 2026, you aren’t just buying a patient list and a building. You’re buying decades of "that’s how we’ve always done it."

You may already be feeling it. The friction that occurs when your corporate standards meet a legacy team that views "the DSO" as an intruder rather than a partner. That friction isn't just an HR headache; it's a financial drain. It leads to clinician turnover, patient attrition, and a diluted brand.

By the time you’ve spent eighteen months trying to "fix" the culture of an acquired site, you could have built two De Novos that were aligned with your mission from Day 1.

That’s the realization driving the De Novo pivot. We’ve moved past the era of growth at any cost. Today, it’s about growth at the right cost. And in a market where quality practices are commanding 10x+ multiples while harboring deep-seated operational inefficiencies, the "build" option is looking better than the "buy" option every single day.

Why Building from Scratch is the New Competitive Edge

When you opt for a De Novo strategy, you are choosing control over convenience. For a COO, that control is everything.

It means you aren’t inheriting a 20-year-old IT stack or a front-desk workflow that relies on sticky notes. Instead, you are implementing your gold-standard systems from the moment the doors open. But more importantly, you are building the clinical culture from scratch.

In our work with DSOs across the country, we’ve found that the most successful De Novos share three common traits:

1. Clinical Autonomy as a Feature, Not a Bug: They attract top-tier talent by offering the resources of a large group with the clinical freedom of a private practice.
2. Technological Integration: They leverage the latest in AI-driven diagnostics and patient management from the jump, avoiding the "integration lag" of acquired sites.
3. Culture-First Staffing: They don’t just fill seats; they curate a team that actually wants to be there.

It’s that simple. And it’s working.

When you build a De Novo, you aren't fighting an uphill battle against an existing team's habits. You are the architect of the habits. This leads to a higher "Clinical ROI", where your providers are more productive because they are operating in a system designed for their success, not one they are trying to bypass.

The Staffing Wall: The Greatest Risk to the De Novo Model

Here is the catch. You can have the best real estate in the city. You can have the most advanced equipment and a sleek, modern brand. But if you don't have the right provider in the chair on opening day, your De Novo is just an expensive hobby.

In 2026, the clinician shortage hasn't gone away; it has evolved. Dentists and specialists are more selective than ever. They aren't just looking for a paycheck; they are looking for a "vibe" and a career path. This is especially true in the FQHC space and rural markets where the need for high-quality dental and clinical staffing is at an all-time high.

If you’re a COO planning five De Novo openings this year, your biggest stressor isn't the contractor, it’s the recruitment funnel.

That’s where the wheels usually fall off. Traditional recruitment models are often too slow or too transactional for the De Novo pace. You need a partner who understands that a De Novo hire is different from an M&A retention. You need a "culture-fit" provider who is an entrepreneur at heart, someone who is excited to build a patient base from zero, not someone who wants to coast on an existing one.

How We Build Your "Foundational Team"

At Arthur Marshall, we’ve refined a recruitment approach specifically for the De Novo model. We don't just send you resumes; we find the clinicians who will become the face of your new location.

We start by understanding your "DNA." What makes your DSO different? Is it your focus on advanced technology? Your commitment to Medicaid or FQHC populations? Your path to equity? We take that story to the market.

We’re not just watching the market, we’re building it. Our team conducts deep-dive searches that go beyond the job boards. We look for the "passive" candidates, the high-performing associates who are tired of being a cog in a machine and are ready to lead a new office.

We handle the heavy lifting:

• Vetting for Culture Fit: We ensure the candidate aligns with your specific operational standards.
• Managing Expectations: We bridge the gap between your corporate goals and the clinician’s personal aspirations.
• Speed to Hire: Because an empty chair in a De Novo is a burning pile of cash.

We’ve seen it time and again: a DSO spends millions on a beautiful new build, only to have it sit idle or underperform because the "founding" dentist wasn't the right fit. We exist to make sure that doesn't happen to you.

Organic Growth: The Valuation Hedge

Let’s talk about the CFO’s perspective for a moment. Why are they suddenly so high on De Novos?

It’s about the "Valuation Reset." In 2026, investors and PE firms are looking past the top-line revenue. They are looking at the quality of earnings and the sustainability of the growth. A DSO that grows solely through acquisitions often looks like a "house of cards", a collection of disparate cultures and systems held together by hope and duct tape.

A DSO that grows through De Novos looks like a brand.

Each new location reinforces the value of the platform. The margins are cleaner. The systems are unified. The clinician turnover is lower. This "operational maturity" is what commands the highest multiples in today’s market.

Yes, De Novos take longer to "ramp." Yes, they require a different set of muscles than M&A. But the long-term viability they provide is your best hedge against market volatility.

The Path Forward

If you are feeling the "M&A burnout": if you are tired of overpaying for practices only to spend the next two years fighting with the staff: it might be time to pivot.

The shift toward De Novo growth isn't just a trend; it's a sign of a maturing industry. It’s a move toward excellence over convenience. It’s about building something that lasts.

At Arthur Marshall, we are honored to partner with COOs who are making this transition. We believe that the heart of every successful dental practice is the person behind the mask. Whether you are building your first De Novo or your fiftieth, the quality of your provider will be your ultimate differentiator.

If you’re ready to stop "buying" problems and start building solutions, let’s talk. We’d love to show you how our retained search model can provide the foundational talent your next location needs to thrive.

Building from the ground up is hard. But with the right team in place, it’s the most rewarding work you’ll ever do.

Let's build something great together.